Why the study?
Drug safety remains a major challenge in the development of antienterovirus drugs.
Avoenin, a compound purified from avocado, demonstrates potent and specific in vitro activity against EV-D68 by inhibiting the viral uncoating step.
Answers are grounded in this paper and cite their sources.
Supports avoenin as EV-D68 lead compound; leaves open in vivo efficacy and clinical translation.
One of the major challenges in development of antienterovirus (EV) drugs is in the safety of the drug. Here, we attempted to identify anti-EV compounds from an edible plant extract library and found potent antienterovirus D68 (EV-D68) activity in avocado ( Persea americana ). The purified identity is determined as 2 R,4 R -(12 Z,15 Z )-heneicosa-12,15-diene-1,2,4-triol, named avoenin. Avoenin shows an EC 50 of 2.0 μM for EV-D68 (Fermon) infection with CC 50 of >150 μM in RD cells by targeting the uncoating step of EV-D68 infection. Resistant mutations of EV-D68 (VP3-V24I, S173P, and S180G) to avoenin confer cross-resistance to pleconaril, an uncoating inhibitor of EV-D68. The inhibitory effect of avoenin is substantially specific to EV-D68 among the EVs. This work reveals avoenin as the identity of anti-EV-D68 activity in avocado and offers insights into development of a novel and effective strategy to overcome EV-D68 infection and its related respiratory diseases.
No takes yet. Share an insight, caveat, or question.
Arita et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: